Roxanna Usticke, LICSW is a
Specialist based in Manchester, New Hampshire. Roxanna Usticke is licensed to practice in * (Not Available) (license number ) and her current practice location is
401 Cypress St, Manchester, New Hampshire. She can be reached at her office (for appointments etc.) via phone at
(603) 668-4111.
NPI number for Roxanna Usticke is 1407136286 and her current mailing address is 2 Wall St Ste 300, Manchester, New Hampshire. She
does not participate in medicare program and thus does not accept medicare assignments. Her NPI Number is 1407136286.
Healthcare Provider's Profile
| Full Name | Roxanna Usticke |
|---|
| Gender | Female |
|---|
| Speciality | Specialist |
|---|
| Location | 401 Cypress St, Manchester, New Hampshire |
|---|
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
NPI Data:
- NPI Number: 1407136286
- Provider Enumeration Date: 08/24/2011
- Last Update Date: 03/27/2018
Medical Identifiers
Medical identifiers for Roxanna Usticke such as npi, medicare ID, medicare PIN, medicaid, etc.
| Identifier | Type | State | Issuer |
| 1407136286 | NPI | - | NPPES |
Medical Taxonomies and Licenses
| Taxonomy | Type | License (State) | Status |
| 1041C0700X | Social Worker - Clinical | 1910 (New Hampshire) | Secondary |
| 174400000X | Specialist | (* (Not Available)) | Primary |
Medicare Part D Prescriber Enrollment
Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Roxanna Usticke is
NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.
Mailing Address and Practice Location
| Mailing Address | Practice Location Address |
Roxanna Usticke, LICSW 2 Wall St Ste 300, Manchester, NH 03101-1518 Ph: (603) 668-4111 | Roxanna Usticke, LICSW 401 Cypress St, Manchester, NH 03103-3628 Ph: (603) 668-4111 |
Reviews and Comments